Subcutaneous Progesterone Supplementation in Patients With Endometriosis

Summary

The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg / day; Crinone, Merck Serono) administered during the luteal phase in term of pelvic pain reduction in patients with grade I-II endometriosis and / or endometrioma \<4 cm subjected to time intercourses or COS/IUI cycles.

Timeline

Start

2016-06

Primary completion

2017-06

Completion

2017-08

Drugs

Indications